Protalix BioTherapeutics (PLX) Reports Q4 Loss of $0.29/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Protalix BioTherapeutics (PLX) Reports Q4 Loss of $0.29/Share

Protalix BioTherapeutics Reports Fiscal Year 2015 Financial Results and Provides Corporate Update

March 8, 2016 7:33 AM EST

Net Income of $58 Million Generated mainly due to the Sale of Our Share in Collaboration to Pfizer

Strong Cash Position of $76.3 Million Projected to Fund Operations into 2018

Special Protocol Assessment for Phase III Clinical Trials of Fabry Disease Filed

Fabry Disease Phase III Trials Expected to Start in First Half of 2016

Two Proof of Concept Studies in Patients of AIR DNaseTM and Oral antiTNF Planned to Start in Mid 2016

CARMIEL, Israel, March 08, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics,... More